This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Xenon Named Life Sciences Company Of The Year By LifeSciences British Columbia

VANCOUVER, Canada, April 8, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award for 2013. 

(Photo:  http://photos.prnewswire.com/prnh/20130408/SF89970)

The LifeSciences British Columbia Awards took take place on Thursday, April 4 at the Vancouver Convention Centre with several hundred guests representing the British Columbia life sciences community. 

"We are honored to be recognized by our industry peers in this way," commented Simon Pimstone, Xenon's President and CEO.  "This is the beginning of a very exciting year for Xenon.  We've worked diligently and deliberately to create strong partnerships with top tier pharmaceutical companies and to develop a deep and diverse pipeline of products.  One of Xenon's early technologies is now in an approved product to treat lipoprotein lipase deficiency, we have a late stage clinical program initiating for our novel pain medicine and an early development stage product for the treatment of anemia.  We look forward to an exciting year at Xenon as our products advance on the market and in the clinic." 

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

For more information regarding this press release, contact: Dr. Robin Sherrington, SVP Business & Corporate Development  (604) 484-3300, ddunn@xenon-pharma.com

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs